Pharmaceutical Market Competition
Auto-discovered topic: Pharmaceutical Market Competition
14 articles analyzed- Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair' Propaganda: 20%
- We're increasing our Eli Lilly price target after another beat-and-raise quarter Propaganda: 30%
- Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge Propaganda: 20%
- Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges Propaganda: 10%
- Novo Nordisk faces off in court with South African weight-loss drug compounder Propaganda: 20%
- Jim Cramer says he can't sell Eli Lilly despite its massive run up. Here's why Propaganda: 30%
- Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage Propaganda: 20%
- Novo Nordisk rolls out Wegovy pill in the UAE — testing appetite outside the U.S. with first global launch Propaganda: 10%
- CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans Propaganda: 20%
- Novo Nordisk partners with OpenAI as AI drug discovery hopes mount Propaganda: 10%
- J&J tops first-quarter profit estimates even as Stelara sales plunge Propaganda: 20%
- Why J&J thinks its new psoriasis pill could be one of its biggest drugs ever Propaganda: 20%
- Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk Propaganda: 10%
- Novo Nordisk’s Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominance Propaganda: 10%